In soft tissue sarcoma, pazopanib improves PFS without affecting HRQoL
the ONA take:
Pazopanib improved progression-free survival but did not impact health-related quality of life in patients with soft tissue sarcoma who experienced disease progression during or after prior chemotherapy, according to a new study published in the journal Cancer.
The global, double-blind, phase III PALETTE trial found that pazopanib 800 mg as second-line or later treatment improved median progression-free survival by 3 months compared with placebo in patients with advanced soft tissue sarcoma. Researchers also found that the most common adverse events associated with pazopanib treatment were diarrhea, fatigue, hypertension, nausea, and weight loss.
Researchers also conducted an exploratory analysis to evaluate the impact of pazopanib treatment on health-related quality of life. Patients were assessed using the 30-item core EORTC Quality-of-Life Questionnaire at baseline and at 4, 8, and 12 weeks of treatment.
Results showed that there was no statistically significant different in global health status between pazopanib and placebo; however, those receiving pazopanib reported significantly worse scores for diarrhea, fatigue, loss of appetite, and nausea/vomiting than those who received placebo. Researchers found that health-related quality of life score tended to decrease over time in both treatment groups.
Pazopanib (Votrient) was initially approved by the U.S. Food and Drug Administration in 2009 for the treatment of patients with advanced renal cell carcinoma.
Pazopanib improved PFS but did not impact HRQoL in patients with soft tissue sarcoma who experienced disease progression during or after prior chemo.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma
- Apalutamide Prolongs Time to Metastasis in Castration-resistant Prostate Cancer
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Travel Distance to Prostate Cancer Treatment Influences Treatment Choice
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|